KRAS and non-small cell lung carcinoma: Notably, in NSCLC and other solid tumors, several KRAS G12C inhibitors are being combined with immune checkpoint inhibitors (ICI), SHP2 inhibitors, EGFR inhibitors, and bevacizumab in clinical trials22,29.